Market Cap
$368.3B
MRK
Merck & Co., Inc.
$143.81 ▼ -1.03%
Prev close $145.31Market cap$368.3B
ConsensusBuy
12-mo target$155.76 (+8.3%)
▲ Bullish
Analyst conviction 7/10
Insider Selling Cluster (5 insiders)33 New Institutional Positions17 Institutional ExitsCongressional Activity (3) Biotech & Drug Discovery
Snapshot
The big-picture read on MRK right now — valuation, ownership and activity at a glance.
Cap Size
Mega Cap
Analyst Consensus
Strong Buy (72%)
Inst. Holders
50 funds
Inst. Value
$187.2B
Inst. Activity
33 buys / 17 sells
Insider Activity
$0.00 buy / $30.0M sell
Insider Net $
-$30.0M
Social Sentiment
70° Bullish
SEC Reports
20
Congressional
6 trades
Price chart 30d -5.2%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 10, 2026 fda_pdufa
PDUFA: MRK — ifinatamab deruxtecan in extensive-stage small cell lung cancer — 2026-10-10
FDA target action date 2026-10-10 for MRK (Merck & Co., Inc.). Drug: ifinatamab deruxtecan. Indicati
Sep 30, 2026 Insider
Coe Mary Ellen was granted 206.455 shares
Director @ $145.31 ($30.0K)
Sep 30, 2026 Insider
Karsanbhai Surendralal Lanca was granted 111.83 shares
Director @ $145.31 ($16.3K)
Sep 30, 2026 Insider
Seidman Christine E was granted 55.915 shares
Director @ $145.31 ($8.1K)
Sep 29, 2026 Event
Kaiser Foundation Health Plan Inc v. Merck & Company Inc. et al
Court ruling (cand) — Docket: 4:21-cv-05497
Sep 21, 2026 Event
Aug 20, 2026 SEC WINREVAIR
Supplemental Approval — Labeling — SOTATERCEPT-CSRK — INJECTABLE
Morgan Stanley upgrades MRK to Overweight — PT $179 (+17.6%)
ANALYST-UPGRADE — Impact 5/10
Aug 19, 2026 Congress
Maria Elvira Salazar buy
$15,001 - $50,000 — House
Analyst ratings buy % +24.1%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
72% rate it Buy or better · 36 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 29, 2026 | Scotiabank | MAINTAIN | Sector Outperform | 56% |
| Sep 10, 2026 | HSBC | MAINTAIN | Buy | 55% |
| Sep 9, 2026 | Leerink Partners | MAINTAIN | Outperform | 49% |
| Sep 8, 2026 | Guggenheim | MAINTAIN | Buy | 52% |
| Sep 4, 2026 | Wells Fargo | MAINTAIN | Overweight | 54% |
| Aug 25, 2026 | Wolfe Research | MAINTAIN | Outperform | 52% |
| Aug 25, 2026 | Argus Research | MAINTAIN | Buy | 54% |
| Aug 21, 2026 | Goldman Sachs | MAINTAIN | Buy | 54% |
| Aug 20, 2026 | BMO Capital | MAINTAIN | Outperform | 53% |
| Aug 20, 2026 | UBS | MAINTAIN | Buy | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 8 | 18 | 10 | 0 | 0 | 72% | |
| Aug 1, 2026 | 9 | 16 | 11 | 0 | 0 | 69% | |
| Jul 1, 2026 | 9 | 16 | 11 | 0 | 0 | 69% | |
| Jun 1, 2026 | 9 | 16 | 11 | 0 | 0 | 69% | |
| May 1, 2026 | 8 | 17 | 10 | 0 | 0 | 71% | |
| Apr 1, 2026 | 8 | 16 | 11 | 0 | 0 | 69% | |
| Mar 1, 2026 | 8 | 16 | 12 | 0 | 0 | 67% | |
| Feb 1, 2026 | 8 | 13 | 13 | 0 | 0 | 62% |
Price targets
Where 25 covering analysts think MRK trades over the next 12 months.
$155.76 +8.3% upside Buy
Current$143.81 Low$105.00 Median$160.00 High$186.00 25 analysts
$105.00$186.00
Analyst rating Buy· 1.8/5 as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
70°
Bullish
BearishNeutralBullish
Recent posts
Value / Margin of Safety Stocks to Consider?
▲ 1 · 💬 2· ⚡ 0.5
Moderna (MRNA) up 70% premarket on positive phase 3 results of first mRNA treatment to prevent cancer (melanoma recurrence)
▲ 1 · 💬 5· ⚡ 0.5
Top Dividend Stocks for 2025: 6 Picks Paying 3%+
▲ 1 · 💬 0· ⚡ 0.5
Market Screener: BAC, JPM, and MRK looking cheap? 📈
▲ 1 · 💬 1· ⚡ 0.5
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
20 SEC filing reports analyzed · 4 bullish, 1 bearish, 1 mixed, 14 neutral · avg impact 2.9/10.
BULLISHANALYST-UPGRADE4/10
Daiwa Capital Upgrades MRK to Outperform — PT $143 (+9.6%)
Aug 12, 2026
MIXEDANALYST-UPGRADE5/10
Morgan Stanley upgrades MRK to Overweight — PT $179 (+17.6%)
Aug 20, 2026
BULLISHANALYST-UPGRADE2/10
CICC initiates coverage on MRK at Outperform
Jun 24, 2026
NEUTRALCOURT-RULING1/10
This is a routine procedural order granting pro hac vice admission for an attorney in the ongoing ca
Sep 12, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 10, 2026
fda_pdufa
PDUFA: MRK — ifinatamab deruxtecan in extensive-stage small cell lung cancer — 2026-10-10
FDA target action date 2026-10-10 for MRK (Merck & Co., Inc.). Drug: ifinatamab deruxtecan. Indication: extensive-stage small cell lung cancer. FDA se
Oct 4, 2026
fda_pdufa
PDUFA: MRK — WELIREG in previously treated patients with advanced RCC — 2026-10-04
FDA target action date 2026-10-04 for MRK (Merck & Co., Inc.). Drug: WELIREG. Indication: previously treated patients with advanced RCC. FDA set PDUFA
Oct 1, 2026
Clinical Trial
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
Phase Phase 2 — COMPLETED
Sep 30, 2026
Clinical Trial
Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder
Phase Phase 2 — COMPLETED
Sep 29, 2026
Clinical Trial
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Phase Phase 2 — COMPLETED
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $2.19 | $1.80–$2.34 | -15.3% | -1.1% | 1↑ 9↓ | $17.3B | 18 |
| Next Q | $1.96 | $1.82–$2.25 | -4.0% | +0.1% | 3↑ 8↓ | $16.9B | 18 |
| Current FY | $2.73 | $2.61–$2.83 | -69.5% | -0.5% | 11↑ 4↓ | $67.1B | 25 |
| Next FY | $9.49 | $8.41–$10.36 | 247.0% | -0.6% | 7↑ 10↓ | $70.2B | 24 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $2.186 | — |
| 7d ago | $2.207 | -0.021 |
| 30d ago | $2.210 | -0.024 |
| 60d ago | $2.268 | -0.083 |
| 90d ago | $2.288 | -0.103 |
Institutional ownership
Which big funds own MRK (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $187.2B total value (1,456,578,135 shares) as of 2026-Q2. Top holders: BlackRock,, VANGUARD, STATE. Net buying activity: 33 institutions added/increased vs 17 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 226,999,837 | $29.2B | 15.6% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 161,323,174 | $20.7B | 11.1% | — |
| STATE STREET CORP | 120,413,256 | $15.6B | 8.3% | — |
| WELLINGTON MANAGEMENT GROUP LLP | 86,249,283 | $11.1B | 5.9% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 67,738,969 | $8.7B | 4.7% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 60,744,214 | $7.8B | 4.2% | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 54,365,289 | $7.0B | 3.7% | — |
| MORGAN STANLEY | 48,641,158 | $6.3B | 3.3% | — |
| FMR LLC | 45,440,355 | $5.8B | 3.1% | — |
| JPMORGAN CHASE & CO | 43,886,420 | $5.7B | 3.0% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| Fisher Asset Management, LLC | ADD | 26,436,284 | 38,516,263 | +45.7% | $4.9B |
| NORGES BANK | NEW | — | 36,983,784 | — | $4.8B |
| Capital International Investors | DOUBLED | 870,261 | 15,386,689 | +1668.1% | $2.0B |
| VOYA INVESTMENT MANAGEMENT LLC | ADD | 5,159,124 | 6,484,756 | +25.7% | $833.3M |
| CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | TRIM | 7,383,088 | 5,398,744 | -26.9% | $693.7M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | ADD | 2,936,330 | 3,966,523 | +35.1% | $509.7M |
| CITIGROUP INC | ADD | 2,779,106 | 3,614,905 | +30.1% | $464.5M |
| NORDEA INVESTMENT MANAGEMENT AB | TRIM | 8,527,993 | 3,503,750 | -58.9% | $445.1M |
| Ensign Peak Advisors, Inc | ADD | 2,613,009 | 3,364,831 | +28.8% | $432.4M |
| BNP PARIBAS FINANCIAL MARKETS | ADD | 2,206,233 | 3,130,937 | +41.9% | $402.3M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
18 insiders, 50 transactions. Net -$30.0M — $0.00 bought, $30.0M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 30, 2026 | Coe Mary Ellen | Director | AWARD | 206.455 | $145.31 | $30.0K |
| Sep 30, 2026 | Karsanbhai Surendralal Lanca | Director | AWARD | 111.83 | $145.31 | $16.3K |
| Sep 30, 2026 | Seidman Christine E | Director | AWARD | 55.915 | $145.31 | $8.1K |
| Aug 13, 2026 | Guindo Chirfi | EVP, Access, Policy & Comms | SELL | 10,000 | $135.00 | $1.4M |
| Aug 12, 2026 | DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | SELL | 600 | $132.04 | $79.2K |
| Aug 12, 2026 | DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | SELL | 11,099 | $131.61 | $1.5M |
| Aug 12, 2026 | Zachary Jennifer | EVP, General Counsel | EXERCISE | 13,433 | $84.71 | $1.1M |
| Aug 12, 2026 | Zachary Jennifer | EVP, General Counsel | EXERCISE | 41,494 | $117.89 | $4.9M |
| Aug 12, 2026 | Zachary Jennifer | EVP, General Counsel | SELL | 80,315 | $133.46 | $10.7M |
| Aug 11, 2026 | DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | SELL | 5,427 | $132.35 | $718.3K |
Congressional trades
MRK trades disclosed by members of Congress, with disclosure delay.
5 members · 4 buys / 2 sells
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Aug 19, 2026 | Maria Elvira Salazar | R | HOUSE | BUY | $15,001 - $50,000 | Merck & Co Inc | Sep 10, 2026(23d) |
| Aug 19, 2026 | Maria Elvira Salazar | R | HOUSE | BUY | $15,001 - $50,000 | Merck & Co Inc | Sep 10, 2026(23d) |
| Aug 7, 2026 | Ro Khanna | D | HOUSE | BUY | $15,001 - $50,000 | Merck & Co Inc | Sep 7, 2026(32d) |
| Feb 4, 2026 | Joshua Gottheimer | D | HOUSE | BUY | $1,001 - $15,000 | Merck & Co Inc | Mar 17, 2026(42d) |
| Jan 13, 2026 | Michael McCaul | R | HOUSE | SELL | $15,001 - $50,000 | Merck & Co Inc | Feb 12, 2026(31d) |
| Jan 10, 2025 | Keith Self | R | HOUSE | SELL | $1,001 - $15,000 | Merck & Co Inc | Jul 1, 2026(538d) |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for MRK.
Shares short
34,430,712
Settlement Sep 15, 2026
Change vs prior
+13.7%
Semi-monthly cycle
Days to cover
4.2
At avg daily volume
Of shares outstanding
≈1.4%
Estimate — not % of float
All MRK filing & press-release reports (20)
- Daiwa Capital Upgrades MRK to Outperform — PT $143 (+9.6%)Aug 12, 2026
- Morgan Stanley upgrades MRK to Overweight — PT $179 (+17.6%)Aug 20, 2026
- CICC initiates coverage on MRK at OutperformJun 24, 2026
- COURT-RULING reportSep 12, 2026
- COURT-RULING reportSep 10, 2026
- COURT-RULING reportAug 28, 2026
- COURT-RULING reportAug 25, 2026
- COURT-RULING reportAug 14, 2026
- CLUSTER reportAug 14, 2026
- CLUSTER reportAug 13, 2026
- CLUSTER reportAug 13, 2026
- CLUSTER reportAug 10, 2026
- CLUSTER reportAug 8, 2026
- COURT-RULING reportAug 8, 2026
- 8-K reportAug 4, 2026
- COURT-RULING reportJul 4, 2026
- COURT-RULING reportJul 3, 2026
- COURT-RULING reportJul 3, 2026
- 8-K reportMay 22, 2026
- DEFA14A reportApr 8, 2026